A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne Vulgaris

Launched by PFIZER · Oct 31, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new medicine called PF-07905428 to see how safe it is and how well it might work for treating acne vulgaris, which is a common skin condition. The study is open to men and women aged 18 to 40 who are generally healthy. If you have moderate to severe acne, you can be part of the study, but you need to have had acne for at least three months.

Participants will apply the study medicine to their face or back every day for either 14 or 28 days, depending on which group they are in. Over about two months, you will visit the study clinic several times for check-ups and to share your experiences. The study team will also call you once at the end of the study. This research is important because it will help us understand if this new medicine is a safe and effective option for treating acne.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who are overtly healthy as determined by medical evaluation.
• • Only for participants who are enrolling with acne vulgaris: diagnosis of acne vulgaris for 3 months or greater
• • For participants enrolling in Cohort 1-3 with acne vulgaris (optional): mild to moderate facial acne vulgaris
• • For participants enrolling in Cohort 4 with acne vulgaris: moderate to severe facial acne vulgaris
• Exclusion Criteria:
• • Participants with very severe acne
• • Participants with autoinflammatory syndromes
• • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease
• • History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
• • Participants with clinically significant laboratory abnormalities